Financial & competing interests disclosure
This research was supported by the nonprofit CoMeD, Inc. and by the nonprofit Institute of Chronic Illnesses, Inc. through a grant from the Brenen Hornstein Autism Research & Education (BHARE) Foundation. David Geier and Mark Geier have been involved in vaccine/biologic litigation and have a patent pending for the treatment of autism spectrum disorders. None of the authors has a financial interest in the Laboratory Corporation of America. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.